Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis

REFERENCES

1. 1.↵
   1. Smolen JS,
   2. Landewé R,
   3. Bijlsma J,
   4. Burmester G,
   5. Chatzidionysiou K,
   6. Dougados M, et al.

   EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Eriksson JK,
   2. Karlsson JA,
   3. Bratt J,
   4. Petersson IF,
   5. van Vollenhoven RF,
   6. Ernestam S, et al.

   Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann Rheum Dis 2015;74:1094-101.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. van den Hout WB,
   2. Goekoop-Ruiterman YPM,
   3. Allaart CF,
   4. de Vries-Bouwstra JK,
   5. Hazes JM,
   6. Kerstens PJ, et al.

   Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:291-9.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. de Jong PH,
   2. Hazes JM,
   3. Buisman LR,
   4. Barendregt PJ,
   5. van Zeben D,
   6. van der Lubbe PA, et al.

   Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology 2016;55:2138-47.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Schipper LG,
   2. Kievit W,
   3. den Broeder AA,
   4. van der Laar MA,
   5. Adang EM,
   6. Fransen J, et al.

   Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology 2011;50:1320-30.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Spalding JR,
   2. Hay J

   . Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006;24:1221-32.

   OpenUrlPubMed
7. 7.↵
   1. Joensuu JT,
   2. Huoponen S,
   3. Aaltonen KJ,
   4. Konttinen YT

   . The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One 2015;e0119683.
8. 8.↵
   1. Bijlsma JW,
   2. Welsing PM,
   3. Woodworth TG,
   4. Middelink LM,
   5. Pethö-Schramm A,
   6. Bernasconi C, et al.

   Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388:343-55.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Verhoeven MM,
   2. Tekstra J,
   3. Welsing PM,
   4. Borm ME,
   5. Bruyn GA,
   6. Bos R, et al.

   Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate. Rheumatology 2020;59:2325-33.

   OpenUrl
10. 10.↵
    1. Institute for Medical Technology Assessment

    . Kostenhandleiding 2016 [Internet. Accessed October 6, 2020.] Available from: www.zorginstituutnederland.nl/over-ons/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg
11. 11.↵
    1. Pennington B,
    2. Davis S

    . Mapping from the health assessment questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results. Value Health 2014;17:762-71.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Zorginstituut Nederland

    . Medicijnkosten.nl. [Internet. Accessed October 6, 2020.] Available from: medicijnkosten.nl
13. 13.↵
    1. Nair SC,
    2. Welsing PM,
    3. Jacobs JW,
    4. van Laar JM,
    5. Rensen WH,
    6. de Wit AG, et al.

    Economic evaluation of a tight-control treatment strategy using an imaging device (handscan) for monitoring joint inflammation in early rheumatoid arthritis. Clin Exp Rheumatol 2015;33:831-8.

    OpenUrl
14. 14.↵
    1. Brand J,
    2. van Buuren S,
    3. le Cessie S,
    4. van den Hout W

    . Combining multiple imputation and bootstrap in the analysis of cost-effectiveness trial data. Stat Med 2019;38:210-20.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Salliot C,
    2. van der Heijde D

    . Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-4.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Burmester GR,
    2. Rubbert-Roth A,
    3. Cantagrel A,
    4. Hall S,
    5. Leszczynski P,
    6. Feldman D, et al.

    Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 2016;75:68-74.

    OpenUrlAbstract/FREE Full Text